Dr. Binder’s research focuses on improving treatment and care for patients with hematologic malignancies. He has contributed to studies addressing gastrointestinal toxicities associated with selinexor-based triplet therapy for relapsed/refractory multiple myeloma. Additionally, he has co-authored research on the use of telehealth and digital technologies to enhance patient care during the COVID-19 pandemic. He has also investigated the impact of COVID-19 on patients with blood cancers, highlighting their increased risks. More recently, his work includes exploring hospital-at-home models to deliver hospital-level oncology care in patients’ homes, aiming to improve convenience and outcomes.
He specializes in the treatment of hematologic malignancies, with a particular focus on lymphoma, including follicular lymphoma . He practices at Jefferson Neoplastic Diseases and is affiliated with Jefferson Methodist Hospital and Thomas Jefferson University Hospital